RE:RE:RE:It may have bottomed. Areal is, this is a standard shelf put in place for almost every fledgling biotech as best practice. They could raise that money at $5 or $15 or $30 per share in future. What is the issue you are concerned with?
If they don't perform at all, it will completely dilute them but did you not see the recent financing news?
I get that you're pissed at losing money like I and many other retailers did 20 months ago but wait for the lawsuit to get back at thomvest.
The action is on Nasdaq - not stockhouse and slack
Arrakis37 wrote:
Market cap is 130M and they need 200M
No news on that. In perfect concordance with Thomvest fraudulent behavior.
Not surprised at all